ChemoCentryx, Inc. – NASDAQ:CCXI
Founder-led company
ChemoCentryx stock price today
$51.99
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
ChemoCentryx stock price monthly change
+0.83%
month
ChemoCentryx stock price quarterly change
+120.86%
quarter
ChemoCentryx stock price yearly change
+54.50%
year
ChemoCentryx key metrics
Market Cap | N/A |
Enterprise value | 3.73B |
P/E | -25.93 |
EV/Sales | 99.43 |
EV/EBITDA | -28.28 |
Price/Sales | 98.69 |
Price/Book | 15.65 |
PEG ratio | 0.20 |
EPS | -1.83 |
Revenue | 37.52M |
EBITDA | -131.93M |
Income | -129.53M |
Revenue Q/Q | 592.34% |
Revenue Y/Y | 76.11% |
Profit margin | -354.69% |
Oper. margin | -350.87% |
Gross margin | 49.36% |
EBIT margin | -350.87% |
EBITDA margin | -351.59% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeChemoCentryx stock price history
ChemoCentryx stock forecast
ChemoCentryx financial statements
| Sep 2021 | 17.69M | -22.30M | -126.09% |
|---|---|---|---|
| Dec 2021 | 2.61M | -35.78M | -1370.39% |
| Mar 2022 | 5.45M | -39.20M | -718.17% |
| Jun 2022 | 11.76M | -32.23M | -274.05% |
| 2022-03-01 | -0.58 | -0.58 |
|---|---|---|
| 2022-05-05 | -0.31 | -0.55 |
| 2022-08-08 | -0.49 | -0.44 |
| Sep 2021 | 454845000 | 138.95M | 30.55% |
|---|---|---|---|
| Dec 2021 | 425652000 | 139.53M | 32.78% |
| Mar 2022 | 440453000 | 181.73M | 41.26% |
| Jun 2022 | 419390000 | 182.86M | 43.6% |
| Sep 2021 | -25.31M | 42.32M | -489K |
|---|---|---|---|
| Dec 2021 | -10.88M | -36.54M | 3.68M |
| Mar 2022 | 8.83M | -21.33M | 3.10M |
| Jun 2022 | -26.12M | 28.08M | 1.86M |
ChemoCentryx alternative data
| Aug 2023 | 178 |
|---|---|
| Sep 2023 | 178 |
| Oct 2023 | 178 |
| Nov 2023 | 178 |
| Dec 2023 | 178 |
| Jan 2024 | 178 |
| Feb 2024 | 178 |
| Mar 2024 | 178 |
| Apr 2024 | 178 |
| May 2024 | 178 |
| Jun 2024 | 178 |
| Jul 2024 | 178 |
ChemoCentryx other data
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Oct 2021 | 0 | 4000000 |
| Dec 2021 | 0 | 37500 |
| Jun 2022 | 0 | 3863 |
| Aug 2022 | 0 | 213760 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | KANAYA SUSAN M director, officer.. | Stock Option (right to buy) | 19,898 | $10.86 | $216,092 | ||
Sale | KANAYA SUSAN M director, officer.. | Common Stock | 19,898 | $50.95 | $1,013,803 | ||
Option | KANAYA SUSAN M director, officer.. | Common Stock | 19,898 | $10.86 | $216,092 | ||
Option | SCHALL THOMAS J. director, officer.. | Stock Option (right to buy) | 130,000 | $14.28 | $1,856,400 | ||
Sale | SCHALL THOMAS J. director, officer.. | Common Stock | 130,000 | $50.24 | $6,531,720 | ||
Option | SCHALL THOMAS J. director, officer.. | Common Stock | 130,000 | $14.28 | $1,856,400 | ||
Option | KANAYA SUSAN M director, officer.. | Stock Option (right to buy) | 31,715 | $6.62 | $209,953 | ||
Option | KANAYA SUSAN M director, officer.. | Stock Option (right to buy) | 14,583 | $6.23 | $90,852 | ||
Sale | KANAYA SUSAN M director, officer.. | Common Stock | 46,298 | $50.17 | $2,322,724 | ||
Option | KANAYA SUSAN M director, officer.. | Common Stock | 31,715 | $6.62 | $209,953 |
| Patent |
|---|
Application Filling date: 16 Nov 2021 Issue date: 8 Sep 2022 |
Grant Utility: 2-oxindole compounds Filling date: 17 Jul 2020 Issue date: 6 Sep 2022 |
Grant Filling date: 10 Jan 2020 Issue date: 6 Sep 2022 |
Grant Filling date: 6 Nov 2020 Issue date: 30 Aug 2022 |
Grant Utility: Immunomodulator compounds Filling date: 23 Jan 2020 Issue date: 30 Aug 2022 |
Application Filling date: 20 Dec 2021 Issue date: 18 Aug 2022 |
Application Filling date: 22 Sep 2021 Issue date: 4 Aug 2022 |
Application Filling date: 8 Dec 2021 Issue date: 28 Jul 2022 |
Application Filling date: 8 Apr 2022 Issue date: 21 Jul 2022 |
Grant Filling date: 11 Aug 2020 Issue date: 12 Jul 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2022 5 May 2022 | Q1 2022 Earnings Call Transcript |
| Q4 2021 1 Mar 2022 | Q4 2021 Earnings Call Transcript |
| Q3 2021 9 Nov 2021 | Q3 2021 Earnings Call Transcript |
| Q2 2021 9 Aug 2021 | Q2 2021 Earnings Call Transcript |
-
What's the price of ChemoCentryx stock today?
One share of ChemoCentryx stock can currently be purchased for approximately $51.99.
-
When is ChemoCentryx's next earnings date?
Unfortunately, ChemoCentryx's (CCXI) next earnings date is currently unknown.
-
Does ChemoCentryx pay dividends?
No, ChemoCentryx does not pay dividends.
-
What is ChemoCentryx's stock symbol?
ChemoCentryx, Inc. is traded on the NASDAQ under the ticker symbol "CCXI".
-
What is ChemoCentryx's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of ChemoCentryx?
Shares of ChemoCentryx can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are ChemoCentryx's key executives?
ChemoCentryx's management team includes the following people:
- Dr. Thomas J. Schall Ph.D. Founder, Pres, Chief Executive Officer & Chairman(age: 66, pay: $1,130,000)
- Ms. Susan M. Kanaya Executive Vice President, Chief Financial & Admin. Officer, Sec. and Director(age: 62, pay: $757,770)
- Dr. Markus J. Cappel Ph.D. Senior Vice President, Chief Bus. Officer & Treasurer(age: 64, pay: $607,520)
- Dr. Rita I. Jain M.D. Executive Vice President, Chief Medical Officer & Executive Employee Director(age: 62, pay: $76,000)
-
Is ChemoCentryx founder-led company?
Yes, ChemoCentryx is a company led by its founder Dr. Thomas J. Schall Ph.D..
-
How many employees does ChemoCentryx have?
As Jul 2024, ChemoCentryx employs 178 workers.
-
When ChemoCentryx went public?
ChemoCentryx, Inc. is publicly traded company for more then 13 years since IPO on 8 Feb 2012.
-
What is ChemoCentryx's official website?
The official website for ChemoCentryx is chemocentryx.com.
-
Where are ChemoCentryx's headquarters?
ChemoCentryx is headquartered at 850 Maude Ave, Mountain View, CALIFORNIA.
-
How can i contact ChemoCentryx?
ChemoCentryx's mailing address is 850 Maude Ave, Mountain View, CALIFORNIA and company can be reached via phone at +1 650 210 2900.
ChemoCentryx company profile:
ChemoCentryx, Inc.
chemocentryx.comExchange:
NASDAQ
Full time employees:
178
Industry:
Biotechnology
Sector:
Healthcare
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California. As of October 20, 2022, ChemoCentryx, Inc. operates as a subsidiary of Amgen Inc.
850 Maude Ave
Mountain View, CALIFORNIA 94070
Mountain View, CALIFORNIA 94070
CIK: 0001340652
ISIN: US16383L1061
CUSIP: 16383L106
